CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on improving adoptive T cell therapies for solid tumors by enhancing their efficacy, safety, and specificity. It utilizes advanced techniques like CRISPR engineering and single-cell analysis to develop strategies that overcome current limitations, such as antigen loss and immune-related adverse eve…
Adoptive T cell therapies are a new class of living drugs, achieving durable results in a subset of patients with aggressive malignancies.
These transformative outcomes are not shared with the majority of patients with solid tumors that remain resistant to current T cell therapies.
As engineered T cell therapy is usually directed against a single antigen, it is especially vulnerable to antigen loss as a tumor resistance mechanism.
Moreover, cancer immunotherapy often leads to severe immune-relat…
TEL AVIV UNIVERSITY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
